https://scholars.lib.ntu.edu.tw/handle/123456789/551146
標題: | HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses | 作者: | Yu M.-L. Lee C.-M. Chuang W.-L. Lu S.-N. Dai C.-Y. Huang J.-F. Lin Z.-Y. Hu T.-I. Chen C.-H. Hung C.-. Wang J.-H. CHI-LING CHEN JIA-HORNG KAO Lai M.-Y. CHEN-HUA LIU TUNG-HUNG SU Wu S.-S. Liao L.-Y. Kuo H.-T. Chao Y.-C. Tung S.-Y. Yang S.-S. PEI-JER CHEN CHUN-JEN LIU DING-SHINN CHEN |
公開日期: | 2010 | 出版社: | University of Chicago Press | 卷: | 202 | 期: | 1 | 起(迄)頁: | 86-92 | 來源出版物: | Journal of Infectious Diseases | 摘要: | Background. With use of peginterferon alfa-2a and ribavirin combination therapy in patients with dual chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, 11.2% of patients achieved clearance of hepatitis B surface antigen (HBsAg) at 6 months after treatment; however, reactivation of HBV DNA was observed in 36.3%. We investigated the predictive potential of HBsAg quantification. Methods. HBsAg quantification was performed in 120 e antigen-negative patients dually infected with HBV and hepatitis C virus and treated with peginterferon alfa-2a/ribavirin for 48 weeks (HCV genotype 1; n = 74) or 24 weeks (HCV genotype 2/3; n = 46). HBsAg was quantified at baseline, week 4, week 12, end of treatment, and 24 weeks after treatment. Results. The baseline median serum HBsAg level was 120 IU/mL and decreased gradually during treatment. Low baseline HBsAg was significantly associated with HBsAg clearance (40% for HBsAg level ?20 IU/mL vs 2.2% for HBsAg level >20 IU/mL; P< .05). A decrease in HBsAg level from baseline to week 12 of 50% was associated with a reduced likelihood of HBV DNA reactivation in patients with baseline undetectable serum HBV DNA (positive predictive value, 89.5%). Conclusions. HBsAg quantification appears to be a useful indicator of posttreatment outcome in patients dually infected with HBV and hepatitis C virus. ? 2010 by the Infectious Diseases Society of America. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953725569&doi=10.1086%2f653209&partnerID=40&md5=e45f5d210ec0839684279a2e61d652a1 https://scholars.lib.ntu.edu.tw/handle/123456789/551146 |
ISSN: | 0022-1899 | DOI: | 10.1086/653209 | SDG/關鍵字: | hepatitis B surface antigen; peginterferon alpha2a; ribavirin; virus DNA; alpha2a interferon; antivirus agent; hepatitis B surface antigen; macrogol derivative; peginterferon alfa-2a; peginterferon alpha2a; ribavirin; virus DNA; article; chronic disease; combination chemotherapy; female; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; major clinical study; male; priority journal; serodiagnosis; virus reactivation; adult; blood; drug administration; genetics; genotype; Hepatitis B virus; Hepatitis C virus; middle aged; virology; virus activation; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon Alfa-2a; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Virus Activation |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。